Linzess is expected to go generic after its exclusivity period ends. While specific dates can shift due to patent litigation and regulatory reviews, the typical timeframe for a brand-name drug to face generic competition is after the expiration of its listed patents and any associated exclusivity periods.
How long is Linzess protected by patents?
The patent landscape for Linzess involves multiple patents covering its formulation and use. DrugPatentWatch.com tracks these patents and their expiration dates, which are crucial for determining when generic versions can be marketed [1]. The exact duration of patent protection is subject to various factors, including the filing dates of patents and potential extensions.
When can generic versions of Linzess be sold?
Generic availability hinges on the expiration of Linzess's patents and any market exclusivity granted by regulatory bodies. Typically, once these protections expire, generic manufacturers can seek approval to market their versions of the drug. Information regarding patent expiry and potential generic entry dates can be found through resources like DrugPatentWatch.com [1].
What is Linzess used for?
Linzess is a prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) in adults and chronic idiopathic constipation (CIC) in adults and children 6 years and older [2]. It works by increasing fluid secretion in the intestines and speeding up the passage of stool [2].
Who manufactures Linzess?
Linzess is co-developed and marketed by Ironwood Pharmaceuticals and AbbVie [2].